Apolipoprotein E ε4 is associated with neuronal loss in the substantia nigra in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 10, Issue 6, 1999, Pages 437-441

  Camicioli, Richard ^a,c   Kaye, Jeffrey ^a,c   Payami, Haydeh ^a,b   Ball, Melvyn J ^a,b   Murdoch, Geoffrey ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Neuronal loss; Substantia nigra

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL COUNT; CELL LOSS; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MESENCEPHALON; NERVE CELL; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SENILE PLAQUE; SUBSTANTIA NIGRA; ALLELE; CLINICAL TRIAL; GENETICS; HIPPOCAMPUS; METABOLISM; MEYNERT BASAL NUCLEUS; PATHOLOGY;

AGE OF ONSET; AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BASAL NUCLEUS OF MEYNERT; FEMALE; HIPPOCAMPUS; HUMANS; MALE; NEUROFIBRILLARY TANGLES; NEURONS; SUBSTANTIA NIGRA;

EID: 0032585952     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017186     Document Type: Article

References (39)

1. Ellis RJ, Caligiuri M, Galasko D, Thal LJ: Extrapyramidal motor signs in clinically diagnosed Alzheimer's disease. Alzheimer Dis Assoc Disord 1996;10:103-114.
2. Poirier J: Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurol Sci 1994;17:525-531.
3. Levy-Lahad E, Bird T: Genetic factors in Alzheimer's disease: A review of recent advances. Ann Neurol 1996;40:829-840.
4. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu C, Wijsman EM, Heston LL, Litt M, Schellenberg GD: Gender differences in apolipoprotein E-associated risk for familial Alzheimer disease: A possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1999;58:803-811.
5. Zareparsi S, Kaye J, Camicioli R, Grimslid H, Oken B, Litt M, Nutt J, Bird T, Schellenberg G, Payami H: Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol 1997;42:655-658.
6. Whitehead AS, Bertrandy S, Finnan F, Butler A, Smith GD, Ben Shlomo Y: Frequency of the apolipoprotein E ε4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:347-351.
7. Martinoli MG, Trojanowski JQ, Schmidt ML, Arnold SE, Fujiwara TM, Lee VM, Hurtig H, Julien JP, Clark C: Association of apolipoprotein ε4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol 1995;90:239-241
8. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S: Apolipoprotein E genotype in a neuropathological series from the consortium to establish a registry for Alzheimer's disease. Ann Neurol 1997;42:319-325.
9. Arendt T, Schindler C, Bruckner M, Eschrich K, Bigl V, Zedlick D, Marcova L: Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein ε4 allele. J Neurosci 1997;17:516-529.
10. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ: The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196.
11. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Peris TT, Lipsitz LA, Hyman BT: Clinical and pathological correlates of apolipoprolein E ε4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
12. Hansen LA, Galasko D, Samuel W, Xia Y, Chen X, Saitoh T: Apolipoprotein E ε4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosci Lett 1994;182:63-65.
13. Morris CM, Benjamin R, Leake A, McArthur FK, Candy JM, Ince PG, Torvik A, Bjertness E. Edwardson JA: Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Neurosci Lett 1995;201:45-48.
14. Benjamin R, Leake A, Ince PG, Perry RH, McKeith IG, Edwardson JA, Morris CM: Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration 1995;4:443-448.
15. Landen M, Thorsell A, Wallin A, Blennow K: The apolipoprotein E ε4 allele does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61:352-356.
16. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK: Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using dissector counts. J Neurol Sci 1997;151:83-87.
17. Kazee AM, Cox C, Richfield EK: Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 1995;9:61-67.
18. Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA: Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc 1997;45:584-589.
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, rev, ed 3. Washington, American Psychiatric Press, 1987.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
21. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42:473-480.
22. Tierney MC, Fisher RH, Lewis AJ, Zorito ML, Snow WG, Reid DW, Nikeuwstraten P: The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology 1988;38:359-364.
23. Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2.
24. Mirra SS, Gearing M, McKeel DW Jr, Crain BJ, Hughes JP, van Belle G, Heyman A: Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: A study of the consortium to establish a registry for Alzheimer's disease (CERAD). J Neuropathol Exp Neurol 1994;53:303-315.
25. Ma ST, Roytta M, Rinne JO, Collan Y, Rinne UK: Single sector and dissector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol 1995;21:341-343.
26. Hixson J, Vernier D: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31: 545-548.
27. Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C: The consortium to establish a registry for Alzheimer's disease (CERAD). IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 1995;45:1991-1995.
28. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J: Clinical and pathological aspects of parkinsonism in Alzheimer's disease: A role for extranigral factors? Arch Neurol 1989;46:651-657.
29. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LR, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
30. Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L: The apolipoprotein E allele ε4 allele is over-represented in patients with the Lewy body variant of Alzheimer's disease. Neurology 1994;44:1950-1951.
31. Gearing M, Schneider JA, Rebeck GW, Hyman BT, Mirra SS: Alzheimer's disease with and without coexisting Parkinson's disease changes: Apolipoprotein E genotype and neuropathologic correlates. Neurology 1995;45: 1985-1990.
32. Dickson DW, Wertkin A, Kress Y, Ksiezak-Reding H, Yen SH: Ubiquitin immunoreactive structures in normal human brains: Distribution and developmental aspects. Lab Invest 1990;63:87-99.
33. Lui Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE: Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.
34. Lippa CF, Smith TW, Saunders AM, Crook R, Pulaski-Salo D, Davies P, Hardy J, Roses AD, Dickson D: Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97-103.
35. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Peterson RC, Parisi J, Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
36. Terry R: The pathology of Alzheimer's disease: Numbers count. Ann Neurol 1997;41:7.
37. al-Chalabi A, Enayat ZE, Bakker MC, Sham PC, Ball DM, Shaw CE, Lloyd CM, Powell JF, Leigh PN: Association of apolipoprotein E ε4 allele with bulbar-onset motor neuron disease. Lancet 1996;347:159-160.
38. Smith RG, Haverkamp LJ, Case S, Appel V, Appel SH: Apolipoprotein E ε4 in bulbar-onset motor neuron disease. Lancet 1996;348:334-335.
39. Bachus R, Bader S, Gessner R, Ludolph AC: Lack of association of apolipoprotein E ε4 allele with bulbar-onset motor neuron disease. Ann Neurol 1997;41:417.